Low-dose aspirin therapy to prevent preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Maternal-Fetal Medicine

Background:

• Pregnancy-associated hypertension, including preeclampsia, is a significant cause of maternal and fetal morbidity.
• Identifying effective preventative strategies for preeclampsia remains a critical area of research in maternal health.

Purpose of the Study:

• To evaluate the efficacy of acetylsalicylate (aspirin) in reducing the incidence or severity of pregnancy-associated hypertension.
• To test the hypothesis that aspirin treatment can mitigate the development of preeclampsia.

Main Methods:

• A randomized, placebo-controlled trial involving 600 nulliparous, healthy women with singleton gestations.
• Participants received either 60 mg of aspirin or a placebo daily from 24 weeks gestation until delivery, following a 2-week run-in period for compliance.
• Serum thromboxane B2 levels were monitored to assess the pharmacological effect of aspirin.

Main Results:

• Preeclampsia occurred in 1.7% of women receiving aspirin versus 5.6% receiving placebo (p = 0.009).
• Severe preeclampsia was observed in one aspirin recipient compared to six placebo recipients (p = 0.06).
• Aspirin treatment led to a significant decrease in serum thromboxane B2 levels, while placebo showed an increase.

Conclusions:

• Daily low-dose aspirin (60 mg) initiated at 24 weeks gestation significantly reduces the occurrence of preeclampsia.
• Aspirin appears to be an effective preventative measure against pregnancy-associated hypertension in high-risk nulliparous women.